Your Medicare Part D Plan Doesn’t Cover A Drug. Now What? Forbes
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression StreetInsider.com
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression BioSpace
Deadly Falls among the Elderly Are on the Rise Scientific American
CCHR: 4.2 Million Vets are Prescribed Dangerous Treatments, Costing $2.4 Billion EIN News
Novel Drug Therapies Could Tackle Treatment-Resistant Depression Scientific American
A Renaissance for Psychedelics Could Fill a Long-Standing Treatment Gap for Psychiatric Disorders Scientific American
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Yahoo Eurosport UK
Avoid routine daily use of fluoxetine for depression after stroke, recommends JAMA study Medical Dialogues
Paranoia vs. anxiety: Symptoms, causes, and more Medical News Today
